Introduction
Obstructive sleep apnea syndrome (OSAS) is characterized by recurrent episodes of sleep apnea that are associated with hypoxia, fluctuations in heart rate and blood pressure, arousal, and consequent fragmented sleep, all of which can result in an activation of the sympathetic nervous system ( 1 -3 ). The most common neuropsychiatric manifestation of OSAS is excessive daytime sleepiness that is secondary to the sleep fragmentation and loss of slow-wave sleep, and other major and long-term manifestations of OSAS are apparent in the cardiovascular system ( 1 ) . Epidemiological studies have thus implicated OSAS as a risk factor for the development of cardiovascular and cerebrovascular diseases ( 4 -6 ) . Moreover, individuals with OSAS manifest increased circulating con-centrations of both endothelin-1 and vascular cell adhesion molecule-1 as well as spontaneous platelet activation, all of which are risk factors for cardiovascular morbidity and mortality ( 7 -9 ) . It is therefore clinically important to assess possible changes in the morphological and physiological features of the vasculature in OSAS in order to be able to predict and to prevent such cardiovascular complications.
The central aortic pressure wave is composed of a forwardtraveling wave generated by left ventricular ejection and a later-arriving reflected wave from the periphery. As aortic and arterial stiffness increase, the transmission velocity of both forward and reflected waves increases, causing the reflected wave to arrive earlier in the central aorta and to augment the central blood pressure in late systole. Augmentation of the central aortic pressure wave is thus a manifestation of wave reflection ( 10 , 11 ) . Central arterial pressure and the degree of its augmentation can be studied noninvasively by sphygmography with the applanation tonometry technique. Pulse wave analysis is simple to perform, rapid, and highly reproducible and provides an indirect assessment of central aortic blood pressure (12) . Aortic pressure augmentation (AG) predicts adverse outcomes in patients with coronary artery disease (13, 14) . Although a possible relation between OSAS and the pathogenesis of atherosclerosis has been suggested (15) , vascular changes in patients with OSAS have not been fully investigated.
In the present study, we examined the augmentation of central aortic pressure as well as conventional cardiovascular risk factors in individuals with OSAS.
Methods Subjects
Forty-five consecutive male patients aged 35 to 78 years (56.0±9.6 years) who were referred to the sleep clinic of Nagoya University Hospital for screening and treatment of OSAS were enrolled in the study. They were not receiving regular medication. As controls, we recruited 71 healthy men aged 40 to 75 years (56.2±7.6 years) without OSAS as determined with a home screening test and self-reported questionnaire and who were free from medication and had no history of cardiovascular disease or diabetes mellitus. The control group had normal electrocardiograms, echocardiographic findings, and blood pressure. The questionnaire was used to obtain data on their medical history, current medications, smoking history, daytime sleepiness on the Epworth sleepiness scale, body mass index (BMI), snoring, and history of observed apnea. Brachial blood pressure was measured by sphygmomanometry with the subject in the sitting position after a 5-min rest. The reported blood pressure values were averages of the second and third measurements. Hypertension was defined as either a systolic blood pressure of > 140 mmHg or a diastolic blood pressure of > 90 mmHg (or both). The study protocol was approved by the Ethics Review Board of Nagoya University School of Medicine (approval No. 238), and written informed consent was obtained from all study participants.
Sleep Study
Standard polysomnography (ALICE 3; Respironics, Murrysville, USA) was performed for all patients with OSAS. The electroencephalogram (C3-A2, C4-A1, O1-A2, O2-A1), electrooculogram, electromyogram, and electrocardiogram were recorded continuously, and respiration was monitored with oronasal thermistors and thoracoabdominal strain gauges. Apnea was defined as a cessation of airflow through the mouth and nose for ≥ 10 s, and hypopnea was defined as a reduction in airflow of ≥ 50% or a reduction in airflow associated with either an oxygen desaturation of > 3% or arousal, also for ≥ 10 s. The apnea-hypopnea index (AHI) was determined as the number of apnea and hypopnea episodes per hour. Individuals with an AHI of ≥ 5/h were diagnosed with OSAS (16) . The time during which nocturnal oxygen saturation (SpO2) was < 90% (oxygen desaturation time) and the lowest SpO2 during sleep were also determined with a pulse oximeter.
Patients with OSAS were stratified according to the AHI. OSAS patients with an AHI of ≥ 20/h were assigned to undergo continuous positive airway pressure (CPAP) for 3 months if they agreed. Nineteen patients received CPAP (CPAP group) and 14 did not (non-CPAP group), with the latter group including nine patients treated with an oral appliance, one with nasal surgery, and four with diet alone instead of CPAP. On the night after the baseline sleep analysis, those patients assigned to receive treatment with CPAP underwent overnight titration of the pressure to adjust it so as either to abolish apnea, hypopnea, and oxygen desaturation or to determine the highest level tolerated. The patients were instructed to use the CPAP device for at least 4 h per night on 70% of nights.
Pulse Wave Analysis
The pulse waveform was obtained from the radial artery at the wrists with a transcutaneous applanation tonometer. Pulse wave analysis was performed with commercially available software (Sphygmocor PVX; AtCor Medical, Sydney, Australia). Pressure was applied to the radial artery with a probe containing a high-fidelity transducer, through which pressure waves were recorded (17) . This technique provides intra-arterial pressure measurements similar to those obtained invasively. The central arterial pressure waveform was derived from the radial artery pressure waveform by the application of a generalized transfer function (18) . AG, defined as the difference in pressure between the second and first systolic peaks ( Fig. 1) , was determined from the central arterial waveform. The aortic augmentation index (AI) was defined as the increment in pressure from the first systolic shoulder (inflection point) to the peak pressure of the aortic pressure waveform expressed as a percentage of the peak pressure (17) . The reproducibility of this method has been found to be acceptable, with the standard deviation of the difference between repeated measurements being 4% to 5% (19) . For each subject, three consecutive waveform recordings were averaged to determine the mean. For sequential waveforms of ≥ 11 s, only those with a pulse wave variation of < 10% were accepted for further analysis.
Visualization of the Vasculature and Blood Analysis
The intima-media wall thickness (IMT) of the carotid arteries was measured by ultrasonography (HDI 3000 instrument; Hitachi, Tokyo, Japan) in all patients with OSAS (20) . It was measured at the site of greatest thickness as well as 1 cm upstream and 1 cm downstream from this site in each longitudinal projection. The three values were then averaged for each projection. The largest of the six averaged IMT values thus obtained (three for the left side and three for the right side) was used as the representative value for each subject. The serum concentrations of total cholesterol, high density lipoprotein (HDL)-cholesterol, low density lipoprotein (LDL)-cholesterol, and triglyceride, and the percentage of glycosylated hemoglobin (HbA1c) were also measured.
Statistical Analysis
Data are presented as means±SD and were compared between groups with Student's unpaired t-test or the χ 2 test. Pearson's correlation was used to evaluate the relation between AG and age, blood pressure, AHI, BMI, smoking, serum concentration of HDL-or LDL-cholesterol, or HbA1c. Multiple regression analysis, including age, blood pressure, AHI, BMI, smoking, serum concentrations of HDL-and LDL-cholesterol, and HbA1c, was performed with a stepwise forward procedure to identify the factors that contribute to an increased AG in OSAS patients, and partial regression coefficients were determined. All analyses were performed with the SPSS 12.0 software package (SPSS, Chicago, USA). A p value of < 0.05 was considered statistically significant.
Results
AG and the AI were significantly greater in OSAS patients than in controls (9.0±4.1 vs. 6.4±3.4 mmHg, p< 0.001; 23.5±8.7 vs. 18.6±9.0%, p= 0.020, respectively) ( Table 1) . There was no significant difference in heart rate between OSAS patients and controls. AG was also significantly greater in hypertensive (11.4±3.5 mmHg, n= 14, p< 0.001) or normotensive (7.9±3.9 mmHg, n= 31, p= 0.013) OSAS patients than in control subjects; in addition, it was significantly greater in hypertensive OSAS patients than in normotensive OSAS patients (p= 0.032).
There was a significant correlation between IMT and AG (r= 0.427, p= 0.032). AG was also significantly correlated with the AHI (r= 0.562, p< 0.001), age (r= 0.356, p= 0.016), and systolic blood pressure (r= 0.391, p= 0.007) but not with heart rate, the serum concentrations of HDL-and LDL-cholesterol or triglyceride, or HbA1c (Table 2) . Multiple regression analysis including the AHI, age, systolic blood pressure, BMI, smoking status, the serum concentrations of HDL-and LDL-cholesterol, triglyceride, and HbA1c revealed that the AHI was the most significant contributing factor to the increased AG in OSAS patients (β= 0.109, r= 0.530, p< 0.001) (Table 3) .
Finally, there was no significant difference in the AHI between the CPAP group and non-CPAP group before treatment. AG, the AI, systolic blood pressure, and diastolic blood pressure were significantly reduced after 3 months of treatment with CPAP in the CPAP group (Table 4) .
Discussion
We have shown that AG was significantly increased in OSAS patients compared with healthy control subjects, and that the AHI was a significant contributing factor to the increased AG. Moreover, AG was significantly reduced in OSAS patients treated with CPAP. These results suggest that OSAS is an important risk factor for increased cardiovascular complications.
In the present study, although hypertension, hyperlipidemia, and diabetes mellitus were common complications in patients with OSAS, neither the serum concentrations of HDL-and LDL-cholesterol or triglyceride, nor HbA1c was significantly correlated with AG. Rather, the AHI was the most important contributing factor to the increased AG. The severity of sleep-disordered breathing and that of associated cardiovascular disease have been found to be important determinants of the prognosis of patients with OSAS (21) (22) (23) . For example, the respiratory disturbance index was shown to be a significant predictor of cardiovascular mortality (21) . We also previously showed that the prognosis of patients with OSAS complicated by cardiovascular or cerebrovascular disease was poorer than that of OSAS patients without such complications (22) . In addition, analysis of cross-sectional data from the Sleep Heart Health Study cohort showed that the AHI was significantly associated with the prevalence of cardiovascular disease (23) . Our present demonstration of a possible link between AG and the AHI provides important information with regard to the predisposition of OSAS patients to premature vascular disease. We propose that, in addition to lifestyle diseases such as hyperlipidemia, hypertension, and diabetes mellitus, the existence of OSAS itself might be a risk factor for cardiovascular disease.
AG was significantly greater in OSAS patients than in healthy controls regardless of the presence of concomitant hypertension. A canine model of OSAS has provided evidence that this condition can lead to a persistent increase in blood pressure not only during the night but also during daytime (24) . We have previously shown that frequent hypoxic episodes with arousal result in an increase in nocturnal blood pressure, and may lead to sustained hypertension and left ventricular hypertrophy, in patients with OSAS (25, 26) . The heart rate fluctuates cyclically in response to apnea or hypopnea and subsequent hyperventilation, with the result that episodes of bradycardia and tachycardia are repeated during the night. OSAS per se might contribute to an altered circadian rhythm of autonomic activity that eventually leads to the development of cardiovascular disease (27) . In addition, OSAS can precipitate myocardial ischemia or a decrease in left ventricular function, either acutely or chronically, in patients with congestive heart failure (28). These long-term cardiovascular complications are presumably secondary to the combined effects of an increase in left ventricular afterload during each futile inspiration caused by obstruction of the upper airway, an increase in heart rate or blood pressure on arousal, hypoxemia and hypercapnia, and the consequent activation of the sympathoadrenal system (29) . All of these changes may also contribute to increased AG, which itself can lead to the development of cardiovascular and cerebrovascular complications. AG, a noninvasively determined manifestation of arterial stiffening and enhanced wave reflection, is a strong and independent risk marker for premature coronary artery disease (13) . Endothelium-dependent vasodilation in resistance vessels has been found to be impaired in patients with OSAS (30) . Moreover, arterial stiffness increases acutely during obstructive apnea in both rapid eye movement (REM) and non-REM sleep in the absence of a measurable change in blood pressure (31) . A meta-analysis of randomized, controlled trials showed that CPAP reduces blood pressure in patients with OSAS and helps to prevent the development of hypertension (32) . Moreover, treatment of OSAS with CPAP has been shown to reduce the risk of fatal and nonfatal cardiovascular events (4) . We recently showed that CPAP treatment resulted in an increase in daytime baroreflex function in addition to an improvement in sleep quality, normalization of nocturnal oxygen desaturation, an increase in plasma NO concentration, and a decrease in 24-h urinary norepinephrine excretion in OSAS patients (2) . We have now demonstrated a direct correlation between the severity of OSAS and AG, and we have shown that AG was significantly reduced in OSAS patients treated with CPAP. Although the effects of CPAP treatment on cardiovascular alterations remain controversial, evidence suggests that changes in vascular function are ameliorated by successful long-term treatment with CPAP. Given the clinical importance of early detection of atherosclerosis for preventing cardiovascular complications, AG may prove to be a useful index in the follow-up of patients with progressive cardiovascular disease secondary to OSAS.
With regard to the limitations of our study, among the 33 patients with an AHI of ≥ 20/h, 14 individuals refused CPAP treatment. Thus, these patients were not randomized into groups that received CPAP for 3 months or did not receive such treatment. The remaining 19 OSAS patients in whom the effects of CPAP were evaluated in the present study may have constituted a somewhat biased group. The effect of CPAP on vascular function described in our study thus requires verification with a large-scale placebo-controlled study.
In conclusion, the severity of OSAS was found to be correlated with AG, a strong indicator of cardiovascular risk, and AG was improved by successful CPAP treatment in patients with moderate to severe OSAS. OSAS itself might therefore contribute to the development of cardiovascular and cerebrovascular complications. 
